EMEA-002608-PIP01-19
Key facts
| Active substance |
2-(3-(1-carboxy-5-[(6-[18F]fluoropyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0357/2019
|
| PIP number |
EMEA-002608-PIP01-19
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Diagnosis of prostate cancer
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Curium Netherlands B.V.
E-mail: regulatory.cyclopharma@curiumpharma.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|